ZENTALIS PHARMACEUTICALS INC's ticker is ZNTL and the CUSIP is 98943L107. A total of 67 filers reported holding ZENTALIS PHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is - and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $10,945,138 | -22.8% | 545,620 | +8.5% | 0.00% | 0.0% |
| Q2 2023 | $14,186,102 | +204.0% | 502,875 | +85.4% | 0.00% | 0.0% |
| Q1 2023 | $4,665,742 | +73.6% | 271,264 | +103.3% | 0.00% | – |
| Q4 2022 | $2,687,863 | +27.4% | 133,459 | +37.0% | 0.00% | – |
| Q3 2022 | $2,110,000 | -78.3% | 97,394 | -71.8% | 0.00% | -100.0% |
| Q2 2022 | $9,715,000 | +18.4% | 345,739 | +94.4% | 0.00% | 0.0% |
| Q1 2022 | $8,205,000 | +223.8% | 177,845 | +490.0% | 0.00% | – |
| Q4 2021 | $2,534,000 | -21.2% | 30,144 | -37.5% | 0.00% | – |
| Q3 2021 | $3,214,000 | -11.8% | 48,231 | -29.6% | 0.00% | – |
| Q2 2021 | $3,643,000 | +58.2% | 68,482 | +29.0% | 0.00% | – |
| Q1 2021 | $2,303,000 | -56.1% | 53,069 | -47.4% | 0.00% | -100.0% |
| Q4 2020 | $5,242,000 | +2013.7% | 100,920 | +1232.5% | 0.00% | – |
| Q3 2020 | $248,000 | -49.0% | 7,574 | -25.2% | 0.00% | – |
| Q2 2020 | $486,000 | – | 10,125 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Paradigm Biocapital Advisors LP | 300,434 | $25,254,000 | 7.21% |
| TYBOURNE CAPITAL MANAGEMENT (HK) LTD | 2,628,409 | $220,944,000 | 6.56% |
| Avidity Partners Management LP | 2,715,000 | $228,223,000 | 4.84% |
| Matrix Capital Management Company, LP | 4,349,279 | $365,600,000 | 4.07% |
| Affinity Asset Advisors, LLC | 117,500 | $9,877,000 | 3.59% |
| Integral Health Asset Management, LLC | 120,000 | $10,087,000 | 2.79% |
| Ghost Tree Capital, LLC | 80,000 | $6,725,000 | 2.41% |
| Ikarian Capital, LLC | 191,140 | $16,067,000 | 2.39% |
| Tri Locum Partners LP | 23,632 | $1,987,000 | 0.78% |
| Eventide Asset Management | 529,000 | $44,468,000 | 0.57% |